Ponaxen is identified on this website as a product containing ponatinib in stated 15 mg and 45 mg strengths. Product-specific manufacturer and authorization information requires verification.
Ponatinib is an oral tyrosine kinase inhibitor used in selected chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treatment settings.
Current U.S. labeling includes ponatinib for selected patients with CML and Ph+ ALL, including specified patients with T315I-positive disease.
ICLUSIG is the established ponatinib reference product in major regulatory markets. Ponaxen should not be described as identical to ICLUSIG without product-specific documentation.
This website identifies Ponaxen in 15 mg and 45 mg strengths. The actual product packaging should be checked to verify the strength.
Current U.S. labeling lists ICLUSIG tablets in 10 mg, 15 mg, 30 mg and 45 mg strengths.
Ponatinib inhibits BCR::ABL1 and other kinases. It also has clinically important activity against T315I-mutated BCR::ABL1.
Ponatinib is classified as a targeted tyrosine kinase inhibitor rather than conventional cytotoxic chemotherapy.
Current U.S. labeled ponatinib regimens are administered once daily, although the prescribed dose depends on the specific indication and treatment setting.
Yes. Current U.S. labeling permits ponatinib administration with or without food.
If a ponatinib dose is missed, the next scheduled dose should be taken the following day. An extra dose should not be taken to make up for the missed dose.
The boxed warning covers arterial occlusive events, venous thromboembolic events, heart failure and hepatotoxicity. Ponatinib requires careful medical monitoring.
Yes. Both arterial occlusive events and venous thromboembolic events have been reported with ponatinib treatment.
Yes. Heart failure, including serious and fatal cases, is included among the major boxed-warning risks associated with ponatinib.
Yes. Ponatinib can cause hepatotoxicity, and serious liver injury and liver failure have occurred. Liver monitoring may be required during treatment.
Hypertension is a recognized adverse reaction associated with ponatinib and should be monitored and managed by a healthcare professional.
T315I is a mutation in BCR::ABL1 that can produce resistance to several earlier kinase inhibitors. Ponatinib retains activity against this mutation.
The current U.S. label specifically states that ICLUSIG is not indicated or recommended for newly diagnosed chronic-phase CML.
Ponatinib can cause fetal harm. Pregnancy and contraception considerations should be discussed with a qualified healthcare professional before and during treatment.
The current U.S. label advises against breastfeeding during ICLUSIG treatment. Patients should discuss feeding options with their healthcare professional.
The original ICLUSIG NDA was submitted by ARIAD Pharmaceuticals. Ponatinib was developed as a targeted tyrosine kinase inhibitor for BCR::ABL1-driven disease.
They should not be described as identical solely because they contain the same active ingredient. Product-specific formulation, manufacturer, packaging and authorization information must be established.
The manufacturer of the specific Ponaxen product is currently listed as information requiring verification. The manufacturer should be confirmed from the product packaging or official regulatory documentation.
A Ponaxen-specific authentication system should not be claimed unless it has been verified through official manufacturer or regulatory documentation.